ERBB2 and breast cancer: Indeed, CD36 targeting, favoring the transition of CSCs in a trastuzumab-sensitive state, could represent an ideal combinatorial approach to boost the anti-CSC activity of trastuzumab and thus increase treatment efficacy in HER2 + BC patients.